BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Philip Morris buys Otitopic and its cardiology inhaler as bidding war for Vectura heats up
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Philip Morris buys Otitopic and its cardiology inhaler as bidding war for Vectura heats up
Aug. 9, 2021
By
Richard Staines
No Comments
Tobacco firm Philip Morris International Inc. has announced another acquisition as it adopts a “beyond nicotine” strategy, snapping up Otitopic Inc., of Los Angeles, for an undisclosed sum.
BioWorld
Deals and M&A
Cardiovascular